Age-associated factors influencing the efficacy of various forms of aerosol therapy

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 15, Issue 3, 2002, Pages 343-345

  Devadason, S G ^a   Le Souef, P N ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AEROSOL; AGE; ASTHMA; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; HUMAN; METERED DOSE INHALER; NEBULIZER;

EID: 0036366540     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/089426802760292690     Document Type: Conference Paper

References (38)

1. Prevalence of asthma in Melbourne schoolchildren
2. Changing prevalence of asthma in Australian children
3. Increase of asthma, allergic rhinitis and eczema
4. Lessons from long-term cohort studies
5. Continued increase in the prevalence of asthma and atopy
6. Dilution of nebulized aerosols by air entrainment in children
7. The effect of breathing pattern on the clearance of aerosols from spacers
8. Drug delivery from holding chambers with attached face-mask
9. Improvement in sodium cromoglycate delivery from a spacer device by use of an anti-static lining, immediate inhalation, and avoiding multiple actuations of drug
10. In vitro assessment of spacer and reservoir devices
11. The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler
12. Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range
13. Delivery of beclomethasone dipropionate from a spacer device: What dose is available for inhalation?
14. Electrostatic charge on a plastic spacer device influences delivery of salbutamol
15. Effect of electrostatic charge, flow, delay and multiple actuations influence the in vitro delivery of salbutamol from different small volume spacers for infants
16. Particle size of beclomethasone dipropionate produced by two nebulizers and two spacing devices
17. Optimum use of a spacer device
18. Inhalational drug delivery from seven different spacer devices
19. Factors affecting in vitro delivery from plastic spacers
20. Minimizing electrostatic charge on a plastic spacer improves both in vitro and in vivo drug delivery
21. High-percentage lung delivery in children from detergent-treated spacers
22. The output of budesonide from spacer devices assessed under simulated breathing conditions
23. Variability of aerosol delivery via spacer devices in young asthmatic children in daily life
24. Comparison of nebulized aerosol deposition in the lungs of healthy adult following oral and nasal inhalation
25. How well do children use dry powder inhalers?
26. Inspiratory capacity through the Turbuhaler in various patient groups
27. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler
28. 99mTc-HFA-BDP inhaled via Autohaler™ in children
29. Lung deposition from the Turbuhaler in children with cystic fibrosis
30. High percentage lung delivery in children from detergent-treated spacers
31. Inhalation therapy in asthma: Nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children
32. Lung deposition of budesonide from turbuhaler in asthmatic children
33. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone
34. Breath-activated MDI provides optimal lung deposition of HFA-beclomethasone compared with press and breathe metered dose inhaler in asthmatic patients
35. Lung deposition characteristics of HFA-134a beclomethasone dipropionate delivered via an Autohaler
36. Lung deposition of coarse CFC vs fine HFA pMDI aerosols of beclomethasone dipropionate (BDP) in asthma
37. Comparison of a breath-activated MDI to coordinated and discoordinated technique with press and breathe HFA-beclomethasone MDIs
38. Lung dose of inhaled drugs in children